Skip to main content

Advertisement

Log in

Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3

References

  1. Brunning RD, Matutes E, Flandrin G, Vardiman J, Bennet J, Head D et al. Acute myeloid leukaemia not otherwise categorised. In: Jaffe E, Harris N, Stein H, Vardiman J (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp 104–105.

    Google Scholar 

  2. Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 2007; 21: 340–350.

    Article  CAS  PubMed  Google Scholar 

  3. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.

    Article  CAS  PubMed  Google Scholar 

  4. Falini B, Nicoletti I, Martelli MF, Mecucci C . Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007; 109: 874–885.

    Article  CAS  PubMed  Google Scholar 

  5. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006; 108: 1999–2005.

    Article  CAS  PubMed  Google Scholar 

  6. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733–3739.

    CAS  PubMed  Google Scholar 

  7. Bolli N, Galimberti S, Martelli MP, Tabarrini A, Roti G, Mecucci C et al. Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol 2006; 7: 350–352.

    Article  PubMed  Google Scholar 

  8. Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006; 66: 3310–3316.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Supported by the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.), BolognAIL, and Deutsche Krebshilfe (70-3173-Tr3). NB is a recipient of a fellowship from FIRC (Federazione Italiana per la Ricerca sul Cancro). We thank Dr Geraldine Boyd for editing the manuscript, Nicole Lange, Barbara Bigerna, Alessandra Pucciarini and Roberta Pacini for the excellent technical support, and Mrs Claudia Tibidò for secretarial assistance. Brunangelo Falini applied for a patent on the clinical use of NPM mutants.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B Falini.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Falini, B., Lenze, D., Hasserjian, R. et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia 21, 1566–1570 (2007). https://doi.org/10.1038/sj.leu.2404699

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404699

  • Springer Nature Limited

This article is cited by

Navigation